What's better than momentum? Mo' momentum.
Let's take a closer look at five of this past week's biggest scorchers.
|
Company |
July 20 | Weekly Gain | My Watchlist |
|---|---|---|---|
|
Alnylam Pharmaceuticals |
$18.74 | 50% | Add |
|
Complete Genomics |
$12.55 | 22% | Add |
|
Statasys |
$56.64 | 19% | Add |
|
NetScout |
$23.20 | 17% | Add |
|
eBay |
$44.85 | 12% | Add |
Source: Barron's.
Alnylam Pharmaceuticals moved higher after its CEO told investors that it's talking to more than one potential partner for its cholesterol drug. The company's injection is targeting patients who don't respond to statins as a way to lower high levels of cholesterol.
Complete Genomics continues to rally on the gene sequencer's new technology that will improve the accuracy and likely reduce the cost of DNA sequencing.
Stratasys shares hit an all-time high last week. Excitement for the prospects of 3-D printing continue to move the few publicly traded players in this niche higher.
Uptime specialist NetScout posted better-than-expected results last week. It also announced that it would be buying Accanto Systems in a move that would beef up its packet flow strategy while adding voice service monitoring to its arsenal of services.
Finally we have eBay coming through with a monster quarter, once again led by booming growth at PayPal.
More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers, there's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.
